Qure Congestive Heart Failure
Congestive heart failure (CHF) is a rapidly progressing and in many cases life-threatening disease affecting 26 million people worldwide. Based on research and development at our recently acquired cardiology gene therapy company InoCard, uniQure is developing a novel gene therapy for the one-time treatment of CHF by selectively restoring cardiac deficiency of the calcium-binding protein S100A1, a master regulator of myocardial function. AAV-S100A1 has proven long-term therapeutic efficacy, safety and reduced mortality in a human-relevant in vivo heart failure model compatible with clinical drug regimens. The first human trial is expected to start in 2016
Appreciate your thoughts on this approach.Thank you
The power of imagination makes us Infinite
